Kynureninase Promotes Immunosuppression and Predicts Survival in Glioma Patients: In Silico Data Analyses of the Chinese Glioma Genome Atlas (CGGA) and of the Cancer Genome Atlas (TCGA).
Gonzalo Pérez de la CruzVerónica Pérez de la CruzJavier Navarro CossioGustavo Ignacio Vázquez CervantesAleli SalazarMario Orozco MoralesBenjamín PinedaPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
Kynureninase (KYNU) is a kynurenine pathway (KP) enzyme that produces metabolites with immunomodulatory properties. In recent years, overactivation of KP has been associated with poor prognosis of several types of cancer, in particular by promoting the invasion, metastasis, and chemoresistance of cancer cells. However, the role of KYNU in gliomas remains to be explored. In this study, we used the available data from TCGA, CGGA and GTEx projects to analyze KYNU expression in gliomas and healthy tissue, as well as the potential contribution of KYNU in the tumor immune infiltrate. In addition, immune-related genes were screened with KYNU expression. KYNU expression correlated with the increased malignancy of astrocytic tumors. Survival analysis in primary astrocytomas showed that KYNU expression correlated with poor prognosis. Additionally, KYNU expression correlated positively with several genes related to an immunosuppressive microenvironment and with the characteristic immune tumor infiltrate. These findings indicate that KYNU could be a potential therapeutic target for modulating the tumor microenvironment and enhancing an effective antitumor immune response.
Keyphrases
- poor prognosis
- long non coding rna
- immune response
- newly diagnosed
- stem cells
- genome wide
- risk assessment
- big data
- electronic health record
- chronic kidney disease
- end stage renal disease
- gene expression
- papillary thyroid
- signaling pathway
- ms ms
- squamous cell carcinoma
- binding protein
- human health
- young adults
- patient reported outcomes
- cell migration
- artificial intelligence
- molecular docking